Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Charles River will perform HTS programs for its clients using AstraZeneca’s state-of-the-art HTS facility.
A 14% hit rate for drug approvals coming out of clinical trials might not sound great, but MIT researchers say this is much higher than they thought.
Rare disease biopharma Shire has kick-started a new mandatory open-access program for research manuscripts to journals it has funded.
No single-source platform for site identification and the lack of a centralized ethics review pathway were cited as slowing the process down.
Hannes Smárason chats with FierceBiotech about WuXi NextCODE's technology, products, investments and the road ahead.
PPD and Quotient have signed up to a new partnership aimed at speeding up the time it takes to make new drugs for children.
The company's Owkin Socrates platform applies transfer and federated learning to clinical research.
Icon has hired a retired colonel who is moving into the biotech sphere as new president of its subsidiary ClinicalRM.
The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.
The $58 million financing round represents biopharma industry's growing interest in genomics data.